Compare TROO & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TROO | TARA |
|---|---|---|
| Founded | 2005 | N/A |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.1M | 236.1M |
| IPO Year | 2008 | 2014 |
| Metric | TROO | TARA |
|---|---|---|
| Price | $2.09 | $4.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $24.40 |
| AVG Volume (30 Days) | 475.6K | ★ 771.6K |
| Earning Date | 05-01-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,948,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.67 | $2.97 |
| 52 Week High | $5.28 | $7.82 |
| Indicator | TROO | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 40.82 | 46.93 |
| Support Level | $1.52 | $3.69 |
| Resistance Level | $2.89 | $4.23 |
| Average True Range (ATR) | 0.36 | 0.20 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 61.08 | 35.71 |
TROOPS Inc is a conglomerate group of various businesses with its headquarters based in Hong Kong. The group is principally engaged in money lending business in Hong Kong providing mortgage loans to high quality target borrowers, property investment to generate additional rental income and the development, operation and management of an online financial marketplace that provides one-stop financial technology solutions including API services by leveraging artificial intelligence, large data and blockchain, and cloud computing (SaaS). It derives revenue from Hong Kong and Australia. Majority of its revenue generates from domestic market.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.